Search clinical trials for: 1L

Total 83 results

Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Refractory Cardiac Arrest Treated On Field By ECMO (ReCATOBE)

Extracorporeal Cardiopulmonary Resuscitation | Extra-hospital Cardiac Arrest

France
William Poncin, PT, PhD

Recruiting

Ventilation Distribution in COPD Patients During Breathing Exercises

Healthy | Chronic Obstructive Pulmonary Disease

Belgium
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC (WUKONG-32)

Non-Small Cell Lung Cancer

China
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Israel, Taiwan, United Kingdom, Chile, Canada, Japan, Brazil
Trishula Therapeutics, Inc.
AbbVie

Recruiting

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Pancreatic Cancer

United States
Sichuan University
Shanxi Provincial Cancer Hospital; Mianyang Central Hospital; Chengdu First people... and other collaborators

Not yet recruiting

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

Advanced Squamous Non-Small-Cell Lung Cancer
Fudan University

Recruiting

Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10) (CASTLE-10)

Hepatocellular Carcinoma

China
Sun Yat-sen University

Not yet recruiting

Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Non Small Cell Lung Cancer | ERBB2 Mutation-Related Tumors | RC48 | Disitamab Vedotin

China
Fudan University

Recruiting

Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)

Advanced Intrahepatic Cholangiocarcinoma

China
Replimune Inc.
Roche Pharma AG

Not yet recruiting

RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recurrent Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma

United States, United Kingdom, France, Germany, Greece
AstraZeneca

Recruiting

Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)

Japan
Jie Li

Recruiting

Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer

Esophagus Cancer

China
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Metastatic Non Small Cell Lung Cancer

Belgium, Australia, United States, Korea, Republic of, Spain, China, France, Thailand, Brazil, Japan, Germany, Romania, Hungary, Italy, Taiwan, Austria, Canada, Hong Kong, Argentina, Netherlands, Chile, Greece, Poland
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer

Cervical Cancer

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer

Advanced Colorectal Cancer
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Intrahepatic Cholangiocarcinoma

China
Eli Lilly and Company
Merck Sharp & Dohme LLC; Loxo Oncology, Inc.

Recruiting

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Pancreatic Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Biliary Tract Neoplasms

Canada, United States, Japan, Australia, France, Korea, Republic of
AstraZeneca

Recruiting

D9319C00001- 1L OC Mono Global RCT (MONO-OLA1)

Ovarian Cancer

China, Vietnam, Russian Federation, Ukraine, South Africa, Turkey, India, Peru, Colombia, Poland, Chile, Philippines
Beijing Cancer Prevention & Treatment Society
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib (FLAME)

Non Small Cell Lung Cancer

China
Seoul National University Hospital

Recruiting

Comparison Between a 1L of Polyethylene Glycol+Ascorbic Acid as a Split Dose Bowel Preparation for Colonoscopy

Colonic Polyp | Colon Adenoma

Korea, Republic of
Harbin Medical University

Recruiting

The Effect of ePRO on Quality of Life and Prognosis of Patients With Unresectable Metastatic Colorectal Cancer

Cancer | Colorectal Cancer Metastatic

China
Queen Elizabeth Hospital, Hong Kong

Recruiting

Efficacy, Tolerance and Safety of Split Dose Bowel Preparation for Colonoscopy: 4L Polyethylene Glycol (PEG) Versus 1L Polyethylene Glycol Plus Sodium Picosulfate-magnesium Citrate (SPMC)

Bowel Preparation Solutions | Colonoscopy

Hong Kong
Merck Sharp & Dohme LLC

Recruiting

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Melanoma

Spain, Poland, United States, Australia, France, Israel, Italy, South Africa, Switzerland, Chile, Greece, Colombia, Hungary
Novartis Pharmaceuticals

Recruiting

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | Large B-cell Lymphoma

Japan, Australia, Germany, Italy, Spain, France, Austria, United States
West Park Healthcare Centre

Recruiting

Partitioned Training of Patients With Idiopathic Pulmonary Fibrosis

Lung; Disease, Interstitial, With Fibrosis

Canada
Simons Searchlight
Boston Children's Hospital; Geisinger Clinic; Simons Foundation

Recruiting

Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight

SMARCA4 Gene Mutation | DDX3X | 16P11.2 Deletion Syndrome | 16p11.2 Duplications | 1Q21.1 Deletion | 1Q21.1 Microduplication Syndrome (Disorder) | ACTL6B | ADNP | AHDC1 | ANK2 | ANKRD11 | ARID1B | ASH1L | BCL11A | CHAMP1 | CHD2 | CHD8 | CSNK2A1 | CTBP1 | CTNNB1 Gene Mutation | CUL3 | DNMT3A | DSCAM | DYRK1A | FOXP1 | GRIN2A | GRIN2B | HIVEP2-Related Intellectual... and other conditions

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Carcinoma, Renal Cell

Spain, United States, Australia, Canada, Chile, Colombia, France, Hungary, Israel, Korea, Republic of, Netherlands, New Zealand, Poland, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)-China Extension Study

Head and Neck Squamous Cell Carcinoma

China
Abcuro, Inc.
Syneos Health

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Inclusion Body Myositis

United States, Australia, Belgium, France, Canada, Germany, United Kingdom
AstraZeneca

Active, not recruiting

PICAROS - Acalabrutinib RWE on 1L CLL in Spain (PICAROS)

Chronic Lymphocytic Leukemia

Spain
Regeneron Pharmaceuticals

Active, not recruiting

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Advanced Non-small Cell Lung Cancer

United States
AstraZeneca

Active, not recruiting

A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC) (TopDouble)

Biliary Tract Cancers

China
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Spain, Hong Kong, Argentina, China, Netherlands, France, Brazil, Belgium, Canada, Germany, Greece, Italy, Japan, Turkey, Ukraine
Guangdong Association of Clinical Trials

Active, not recruiting

Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC (FLOWERS)

Carcinoma, Non-Small-Cell Lung

China
GlaxoSmithKline

Active, not recruiting

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer (ZEAL-1L)

Lung Cancer, Non-Small Cell

Argentina, France, Spain, Italy, Belgium, Korea, Republic of, United States, Mexico, Hungary, Sweden, Turkey, Ireland, Greece, Russian Federation, Germany, Netherlands, Bulgaria, Romania, Brazil, United Kingdom, Poland, Australia, C... and more
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (KEYNOTE-B61)

Renal Cell Carcinoma

Poland, Australia, United States, Canada, France, Hungary, Ireland, Italy, Korea, Republic of, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010) (LEAP-10)

Head and Neck Squamous Cell Carcinoma

United States, Australia, Brazil, Canada, China, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

Korea, Republic of, United States, Taiwan, China, Argentina, Australia, Brazil, Chile, France, Germany, Italy, Japan, Poland, Spain, United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy (CheckMate722)

Non-Small-Cell Lung Carcinoma

United States, China, Taiwan, Spain, Korea, Republic of, France, Canada, Hong Kong, Japan, Singapore
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Carcinoma, Non-squamous Non-small-cell Lung

Poland, Korea, Republic of, Ukraine, United States, Argentina, Australia, Austria, Canada, France, Japan, New Zealand, Romania, Russian Federation, Taiwan, Turkey, United Kingdom, Brazil, Colombia, Germany, Spain
Shanghai Henlius Biotech

Active, not recruiting

A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Carcinoma | Non-Small-Cell Lung

China
Radboud University Medical Center

Completed

Effect of Low-volume (1L) vs Intermediate-volume (2L) Bowel Preparation on Cost-effectiveness and Quality of Life (RESULT)

Colorectal Cancer | Colonic Polyp

Netherlands
National Cancer Institute (NCI)

Completed

Continuous Infusion of rhIL-15 for Adults With Advanced Cancer

Lymphoma | Carcinoma

United States
Mansoura University

Active, not recruiting

Comparison of Zero- and Two-centimeter Distance From Sapheno-femoral Junction in Laser Ablation of Varicose Vein

Varicose Veins | Venous Insufficiency | Venous Leg Ulcer | Venous Reflux

Egypt
Sichuan University
Afﬁliated Hospital of North Sichuan Medical College; Affiliated Hospital of...

Completed

Effect of Lactulose and/or Polyethylene Glycol Solution for Bowel Preparation for Colonscopy Procedures

Colonoscopy

China
VA Office of Research and Development

Completed

Integrated CBT-I and PE on Sleep and PTSD Outcomes (Impact Study)

Posttraumatic Stress Disorders | Chronic Insomnia

United States
Calithera Biosciences, Inc

Terminated

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE)

Non-Small Cell Lung Cancer | Non-squamous Non-small-cell Lung Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | KEAP1 Gene Mutation | NRF2 Gene Mutation | NFE2L2 Gene Mutation

United States
Hospital Clinic of Barcelona
Fundacion Clinic per a la Recerca Biomédica; Casen Recordati S.L.

Completed

Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy (LOWOL)

Colorectal Cancer

Spain
Norgine
Xolomon Tree S.L.

Completed

Real Word Evidence With 1L Polyethylene Glycol (PEG)+ Ascorbic Acid in Iberia

Colon Cancer | Colon Disease | Colon Cleansing

Spain, Portugal

Search clinical trials for: 1L

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations